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INTRODUCTION  
Hypertension is currently the leading risk resulting in 
considerable death and disability worldwide and accounted 
for 9.4 million deaths and 7 per cent of disability adjusted 
life years (DALYs) in 2010
1
. India, the world's largest 
democracy, is undergoing a rapid economic growth. This 
growth has been accompanied by demographic, lifestyle 
and cultural changes which have had a large impact on the 
health profile of India's citizens and placed a significant 
strain on the country's healthcare system
2-4
. In India, 
hypertension is the leading non communicable disease 
(NCD) risk and estimated to be attributable for nearly 10 
per cent of all deaths
5
. Adult hypertension prevalence has 
risen dramatically over the past three decades from 5 per 
cent to between 20-40 per cent in urban areas and 12-17 
per cent in rural areas
6-7
. The number of hypertensive 
individuals is anticipated to nearly double from 118 
million in 2000 to 213 million by 2020.
7
 It is estimated 
that 16 per cent of ischaemic heart disease, 21 per cent of 
peripheral vascular disease, 24 per cent of acute 
myocardial infarctions and 29 per cent of strokes are 
attributable to hypertension underlining the huge impact 
effective hypertension prevention and control can have on 
reducing the rising burden of cardiovascular disease 
(CVD)
8
. 
The management of hypertension involves lifestyle 
modifications, pharmacological treatment, or both. Weight 
reduction for overweight or obese patients, adherence to 
the Dietary Approaches to Stop Hypertension (DASH) 
diet, moderate consumption of alcohol, and physical 
activity are all essential to decreasing blood pressure and 
enhancing the efficacy of pharmacotherapeutic regimens
9
. 
Pharmacological treatment includes management with one 
or more agents belonging to the following drug classes: 
thiazide diuretics, beta blockers, calcium-channel blockers, 
angiotensin-converting enzyme (ACE) inhibitors, and 
angiotensin receptor blockers (ARBs). Although thiazide 
diuretics are recommended as the first-line therapy for 
most patients with hypertension, beta blockers have a 
compelling indication for use in patients with high-risk 
conditions such as heart failure, MI, coronary disease, and 
diabetes
9,10
. Beta blockers exert antihypertensive effects by 
reducing myocardial contractility, heart rate, and cardiac 
output
9,10
. Central inhibition of sympathetic nervous 
system outflow, inhibition of the renin–angiotensin system 
by reducing renin release from the juxtaglomerular 
apparatus, and resetting or altered sensitivity 
of baroreceptors may also contribute to the BP-lowering 
effects of this drug class
11-13
. Beta blockers differ in many 
of their pharmacological properties, including β1 and β2- 
adrenergic receptor selectivity and vasodilatory 
capabilities.  
Nebivolol (α,α′-[iminodimethylene]bis[6-fluoro-2-
chrommethanol) belongs to third generation selective β-
Adrenergic Receptor Blocker is somewhat different from 
its class. It is novel in its class by possessing other 
favourable effect apart from anti hypertensive property. It 
appears to be the most selective β1 receptor antagonist 
available clinically and is devoid of intrinsic 
sympathomimetic activity, inverse agonistic activity, and 
α1 receptor blocking properties
10
. It does not alter exercise 
capacity in healthy individuals but does inhibit both ADP 
and collagen-induced platelet aggregation
11
. Along with 
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peripheral vasodilatation and nitric oxide (NO)-induced 
benefits such as antioxidant activity and reversal of 
endothelial dysfunction nebivolol facilitates better 
protection from cardiovascular events
14,15
. 
              In dec 18, 2007 nebivolol was approved by FDA 
for treatment of hypertension. In Europe it is also approved 
for heart failure. Nebivolol is the racemic mixture of 2 
isomers with 4 asymmetric centres and is at present the 
only β-blocker whose structure differs fundamentally from 
that derived from propranolol. The d-isomer has the SRRR 
configuration, and the l-isomer is RSSS. The d-isomer is 
the active b-blocking component, while the l-isomer is 
responsible for the release of nitric oxide
16-18
. 
 
Structure of Nebivolol 
 
Ball-and-stick model of nebivolol molecule 
 
Mechanism of action; 
A number of mechanisms combine to determine the 
hemodynamic changes induced by nebivolol. These 
include a negative chronotropic effect, inhibition of 
sympathetic outflow from cerebral vasomotor centers, 
inhibition of peripheral α1-adrenoceptors
19
, suppression of 
renin activity, and most importantly, decreased peripheral 
vascular resistances. Interestingly, although nebivolol's D-
isomer appears to possess relevant selective β1 blocking 
and mild vasodilatory properties, the L-isomer determines 
the stimulation of eNOS and subsequent endothelium-
dependent vasodilation
20
, and only at suprapharmacologic 
dosages does it exert β-blocking effects21. 
These differences between isomers might well have 
clinical implications, and separate administration of 1 of 
the 2 could be hypothesized for selected patients. In 
combination, the 2 stereoisomers of nebivolol cooperate in 
determining the hemodynamic impact of the drug
21,22
. The 
very high selectivity for β1 versus β2-adrenergic receptors 
of the d-isomer explains the limited effects on airway 
reactivity and insulin sensitivity
23,24
 as well as the lesser 
negative inotropic effect of nebivolol in patients with heart 
failure
14,25
. This selectivity tends to be overcome at 
dosages >10 mg and in poor metabolizers, causing the loss 
of this positive characteristic of nebivolol.  
Pharmacokinetic Profile
26
: 
Nebivolol is well absorbed after oral administration. The 
metabolism of nebivolol is subject to genetic 
polymorphism; phenotypically, individuals may be 
characterised as „poor‟ (slow) or „extensive‟ (fast) 
metabolisers. After a single 5mg oral dose, peak plasma 
drug concentrations (Cmax) for unchanged d, l-nebivolol 
were 1.48 μg/L in fast metabolisers and for active fractions 
of d- and l-nebivolol plus their corresponding hydroxylated 
metabolites were 7.3 and 13.1 μg/L, respectively, in 
hypertensive patients. Repeated doses increased the 
Cmax values for the individual d- and l-enantiomers and 
their respective metabolites. Time to Cmax after oral 
administration of nebivolol is reported to be about 0.5 to 
2.0 hours and is not significantly affected by the presence 
of food. Generally, steady-state plasma concentrations are 
achieved within 1 day for nebivolol and within a few days 
for the active metabolites. Obesity does not appear to 
affect the total distribution volumes and total body 
clearance rates (per kilogram body weight) of unchanged 
nebivolol (racemate or each enantiomer). 
Extensive first-pass metabolism after oral administration 
of nebivolol produces active β-blocking hydroxy-
metabolites. Elimination half-lives for the unchanged 
compound (racemate or each enantiomer) average about 10 
hours, but are reported to increase by up to 5 times in poor 
metabolisers. Elimination half-lives for the hydroxy-
metabolites of both enantiomers average about 24 hours in 
extensive metabolisers, but are almost doubled in poor 
metabolisers. The absolute oral bioavailability of nebivolol 
is 12% in extensive metabolizers and 96% in poor 
metabolizers. However, a safety trial in both extensive and 
poor metabolizers has shown no safety or efficacy 
differences between these patient groups. One week after 
administration, 38 and 48%, respectively, of the nebivolol 
dose is excreted in urine and faeces; unchanged nebivolol 
accounts for <0.05% of the amount recovered in the urine. 
Plasma concentrations of nebivolol (both enantiomers) and 
its hydroxy metabolites are elevated in patients with renal 
disease
26
. 
Pharmacodynamic properties: 
 Nebivolol has a hemodynamic profile different from 
classic β receptor antagonists such as atenolol, propranolol, 
and pindolol. It acutely lowers arterial blood pressure 
without depressing left ventricular function, and reduces 
systemic vascular resistance. This reduction in systemic 
vascular resistance is due to a direct vasorelaxant effect 
that is mediated at least in part by NO
27
. Evidence of 
eNOS dependent vasodilator effects of nebivolol was also 
reproduced in humans in the arterial and venous 
circulation, where both direct endothelium-dependent 
vasodilation and increased responsiveness to other specific 
stimuli such as hyperemia were reported Remarkably, the 
magnitude of this effect was similar across hypertensive 
patients and healthy volunteers, which shows that the 
presence of vascular disease does not limit the 
endothelium-dependent vasodilator capacity and 
hemodynamic benefit  achievable pharmacologically
28,29
. 
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Effects of intra-arterial infusion of nebivolol on forearm 
blood flow in healthy control subjects and patients with 
essential hypertension
28,30
. In both groups, nebivolol but 
not atenolol caused vasodilation, an effect that was 
antagonized by endothelial nitric oxide synthase (eNOS) 
inhibition. Nebivolol alone markedly improved endothelial 
function in hypertensive patients
31
. Nebivolol, but not 
other β-blockers, inhibits phorbolester (PDBu) induced 
superoxide production in neutrophils from 
hypercholesterolemic rabbits
32
. Like other β-blockers, 
nebivolol has important electrophysiologic properties 
because it increases the ventricular fibrillation threshold, 
therefore reducing ventricular arrhythmias in animal 
models of ischemia- or drug-induced cardiomyopathy
33
, 
and it reduces QT dispersion, a marker of arrhythmic 
risk
34
. Further, nebivolol reduces P-wave dispersion on the 
electrocardiogram, which would attenuate the risk of atrial 
fibrillation, one of the leading causes of death in heart 
failure and hypertension
35
. 
In another study, the effect of nebivolol on small artery 
distensibility in patients with hypertension was compared 
with that of atenolol. Both drugs were equivalent in 
reducing BP, but only nebivolol improved small artery 
distensibility, a measure of arterial compliance or 
“stiffness”36. Arterial stiffness has been shown to be an 
independent predictor of mortality in patients with 
essential hypertension. Drugs that reduce stiffness may 
therefore confer a survival advantage
37
. In an animal 
model comparison with atenolol, nebivolol infusion 
showed a statistically significant reduction in a measure of 
arterial distensibility, namely pulse wave velocity, with no 
change in mean arterial pressure
38
. In contrast, atenolol had 
no effect on pulse wave velocity despite a small drop in 
mean arterial pressure. This difference suggests that the 
release of NO mediated by nebivolol, independent of a 
beta-adrenoceptor-dependent mechanism, an effect not 
seen with older beta-blockers such as atenolol, may be of 
particular benefit in patients with impaired arterial 
compliance, such as those with isolated systolic 
hypertension
38
. 
In vitro, nebivolol, propranolol, and carvedilol have all 
been shown to inhibit both adenosine diphosphate- and 
collagen-induced platelet aggregation; however, the effect 
of nebivolol appears to be significantly greater, and it is 
lost after inhibition of eNOS
39
. Further, therapy with 
nebivolol causes a significant decrease in mean platelet 
volume and plasma sP-selectin levels and is associated 
with favorable modifications of hemostatic and fibrinolytic 
status, including reduced plasma levels of fibrinogen 
plasma activator inhibitor-1, homocysteine, and 
endothelin-1
40
.  
Recently it was demonstrated that nebivolol, but not other 
β-blockers, improves endothelial function, reduces 
vascular superoxide production via prevention of eNOS 
uncoupling, reduces vascular macrophage infiltration, and 
inhibits NAD(P)H oxidase-dependent superoxide 
production in neutrophils isolated from hyperlipidemic 
rabbits
41
. Similarly, in a model of angiotensin II-induced 
oxidative stress
42
, we observed that nebivolol, but not 
metoprolol, normalizes endothelial function, reduces 
superoxide formation, increases NO bioavailability, and 
inhibits up-regulation of the activity and expression of the 
vascular NAD(P)H oxidase
42
, thus preventing eNOS 
uncoupling. Finally, nebivolol treatment has been 
demonstrated to inhibit the oxidized low-density 
lipoprotein-induced inactivation of NO
43
 and to reduce the 
levels of the circulating eNOS inhibitor asymmetric 
dimethyl-arginine, which likely contributes to increase 
vascular NO bioavailability
44
. 
Nebivolol causes down-regulation of a number of genes 
involved in inflammatory processes, oxidative stress, and 
smooth muscle cell proliferation
45,46
. Such antiproliferative 
and proapoptotic effects have obvious potential 
implications in the prevention and treatment of 
atherosclerosis. Of interest, this antiproliferative action 
(along with that of other NO donors), although being NO-
mediated, appears to be independent of cyclic guanosine 
monophosphate
47
. In agreement with these findings, 
nebivolol has been shown to inhibit the expression of 
inflammatory proteins and factors involved in vascular 
remodeling such as metalloproteinases and protease 
inhibitor
48-50
. In hyperlipidemic animals, augmentation of 
NO with nebivolol increased plaque stability
51
. Further, 
nebivolol inhibited neointima formation in a murine model 
of vascular injury
49
, and it prevented cardiac and renal 
modifications in a rat model of insulin resistance
52
. Finally, 
nebivolol inhibited the development of atherosclerosis in 
cholesterol-fed rats
53
. 
The primary indications for which nebivolol has been 
developed and studied include systemic hypertension, 
heart failure, and although less data are available, coronary 
artery disease. However, the hemodynamic effect of 
nebivolol appears to be different from that of atenolol. In a 
double-blind, randomized, prospective study in patients 
with essential hypertension, atenolol reduced cardiac 
output, stroke volume, and heart rate. In contrast, nebivolol 
reduced peripheral resistance and increased stroke volume, 
preserving cardiac output. The effects of nebivolol 
demonstrated in this study suggest that the drug may be 
important in treating heart failure, where preservation of 
cardiac output is critical
54
.   
Nebivolol 5 mg/day was compared with metoprolol 100 
mg BID in 80 newly diagnosed hypertensive patients. 
After 6 months of treatment, the researchers found that 
both drugs significantly reduced BP and heart rate, with a 
more profound bradycardic effect seen in the metoprolol 
group. In contrast, only nebivolol significantly reduced 
oxidative stress, insulin resistance index, and plasma levels 
of P-selectin, a cell-surface adhesion molecule believed to 
play a role in the initiation of atherosclerosis
55
. A number 
of randomized, double-blind, placebo-controlled trials 
have investigated the efficacy and tolerability of 5 to 10 
mg of nebivolol therapy in patients with mild-to-moderate 
essential hypertension. Nebivolol has a relatively modest 
impact on diastolic blood pressure
56
, a characteristic that is 
believed to contribute to the safety profile of the drug. 
Nebivolol 2.5–5 mg/day was compared with the calcium 
channel antagonist, amlopidine, 5–10 mg/day in elderly 
patients (≥65 years). In this double-blind, multicenter, 
randomized trial, efficacy was similar between the two 
groups. Both drugs were well tolerated, however, there 
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was a higher incidence of adverse events such as headache 
and ankle edema in the group treated with amlodipine
57
. 
In terms of effectiveness on systolic blood pressure, 
studies suggest that nebivolol compares at the same level 
with other β-blockers and Ca2+-antagonists and is 
somewhat more potent than angiotensin-converting 
enzyme (ACE) inhibitors. The typical onset of maximal 
nebivolol antihypertensive effect occurs after 2 to 8 weeks 
of therapy, which is intermediate between ACE inhibitors 
(slower) and amlodipine (faster). In recent meta-analyses, 
the percentage of patients who achieved target blood 
pressure levels was somewhat greater compared with ACE 
inhibitors and comparable with angiotensin-II blockers or 
Ca
2+
-channel antagonists
58,59,60
. 
The largest double-blind study in hypertension included 
909 patients with mild-to-moderate hypertension. 
Nebivolol in doses of 1.25–40 mg/day were compared with 
placebo over 12 weeks. Placebo-subtracted reductions in 
trough sitting BP (SBP/DBP) ranged from 6.6/5.1–11.7/8.3 
mm Hg and were dose dependent. Reported adverse events 
were: headache (7.1 vs 7.4% placebo, fatigue (3.6 vs 2.5% 
placebo, nasopharyngitis (2.9% vs 7.4% placebo), diarrhea 
(2.8% vs 2.5% placebo) and dizziness (2.8 vs 3.7% 
placebo). The incidence of typical beta-blocker adverse 
effects was very low and no different from placebo 
including erectile dysfunction (0.2% vs 0.0% placebo), 
decreased libido (0.1% vs 0.0% placebo), dyspnea (1.0% 
vs 0.0% placebo) and bradycardia (0.7% vs 0.0% 
placebo)
61
.  
Results of previous pharmacokinetic studies suggest that 
nebivolol 5 mg may not conform completely to the 
definition of a classic beta-blocker demonstrating 
additional antihypertensive effect due to endothelial NO 
release-mediated vasodilation. This meta-analytic   study 
on Efficacy and tolerability of nebivolol compared with 
other antihypertensive drugs showed that nebivolol 5 mg 
achieved similar or better rates of treatment response and 
BP normalization than other drug classes and other 
antihypertensive drugs combined, with similar tolerability 
to placebo and significantly better tolerability than 
losartan, CCAs, other beta-blockers, and all 
antihypertensive drugs combined. Although not definitive, 
this meta-analysis suggests that nebivolol 5 mg is likely to 
have advantages over existing antihypertensives and may 
have a role in the first-line treatment of hypertension
62
. 
In elderly heart failure patients with a wide range of 
ejection fraction, mild and moderate impairment of renal 
function did not interact with the effect of nebivolol on 
clinical outcomes. Furthermore, nebivolol was well 
tolerated in participants of the elderly patient trial with 
moderate renal impairment. Thus, mild to moderate renal 
dysfunction, even in the elderly, should not present a 
limitation to the use of nebivolol in HF patients
63
.  
A post-marketing surveillance study on Efficacy, 
tolerability and safety of nebivolol in patients with 
hypertension and diabetes, Nebivolol treatment was 
associated with a significantly reduced BP, improved 
blood glucose and LDL cholesterol levels and was well 
tolerated in hypertensive patients with concomitant DM
64
. 
A study  on clinical and economic aspects of the use of 
nebivolol in the treatment of elderly patients with heart 
failure shows that nebivolol is well tolerated and effective 
in reducing mortality and morbidity in older patients, and 
that the beneficial clinical effect is present also in patients 
with mildly reduced ejection fraction. Moreover, nebivolol 
appears to be significantly cost-effective when prescribed 
in these patients. However, further targeted studies are 
needed to better define the efficacy as well as safety 
profile in frail and older patients with comorbid diseases
65
. 
Side effect:  
Several studies have suggested that nebivolol has reduced 
typical beta-blocker-related side effects, such 
as fatigue, clinical depression, bradycardia, or impotence
66-
68
. Nebivolol appears to have a minor, if any, effect on 
libido and sexual performance, which likely ensues from a 
compensatory effect of the increased NO release
69
. 
Common adverse effects reported with nebivolol in 
clinical trials included fatigue, headache, dyspnea, 
insomnia, dizziness, and paresthesia; however, the 
incidence of these symptoms was not different in placebo-
treated subjects (0–5%)70. Importantly, nebivolol does not 
appear to modify low-density lipoprotein cholesterol or 
total cholesterol levels, and it does not seem to precipitate 
diabetes. nebivolol's greater selectivity for β1-receptors 
results in improved tolerability: in patients with mild 
asthma, nebivolol induced a mild, clinically insignificant 
reduction in respiratory parameters
71,72
. After a 4- and 12-
week treatment on hypertensive patients, the use of 
nebivolol actually increased peak expiratory flow and 
quality-of-life parameters
73
 
Interaction
74-76
: 
Because it is metabolized by CYP450-2D6, nebivolol is 
potentiated by inhibitors of this enzyme, such as quinidine, 
propafenone, fluoxetine, paroxetine, and any 
coadministration should be avoided. Nebivolol should 
generally be avoided by patients taking other myocardial 
depressants or atrioventricular conduction inhibitors, 
specifically dihydropyridine calcium-channel blockers or 
anti-arrhythmic medications, because of the increased risk 
of bradycardia. No pharmacokinetic interactions were 
observed in healthy adults between nebivolol (10 mg daily 
for 10 days) and furosemide (40 mg single dose), 
hydrochlorothiazide (25 mg once daily for 10 days), or 
spironolactone (25 mg once daily for 10 days). In the case 
of concomitant nebivolol and clonidine (Catapres, 
Boehringer Ingelheim), nebivolol should be discontinued 
several days before the clonidine dose is tapered. 
Contraindication
77
:
  
According to FDA, Nebivolol is associated with a number 
of serious risks. It is contraindicated in patients with severe 
bradycardia, heart block greater than first degree, 
cardiogenic shock, decompensated cardiac failure, sick 
sinus syndrome (unless a permanent pacemaker is in 
place), severe hepatic impairment (Child-Pugh > B) and in 
patients who are hypersensitive to any component of the 
product. Nebivolol therapy is also associated with 
warnings regarding abrupt cessation of therapy, cardiac 
failure, angina and acute myocardial infarction, 
bronchospastic diseases, anesthesia and major surgery, 
diabetes and hypoglycemia, thyrotoxicosis, peripheral 
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vascular disease, non-dihydropyridine calcium channel 
blockers use, as well as precautions regarding use with 
CYP2D6 inhibitors, impaired renal and hepatic function, 
and anaphylactic reactions. 
 
In late August 2008, the FDA issued a Warning Letter to 
Forest Laboratories citing exaggerated and misleading 
claims in their launch journal ad, in particular over claims 
of superiority and novelty of action written that "FDA is 
not aware of any substantial evidence or substantial 
clinical experience that demonstrates that Bystolic 
represents a 'novel' or 'next generation' beta blocker for the 
treatment of hypertension. Indeed, we are not aware of any 
well-designed trials comparing Bystolic to other β-
blockers. Furthermore, FDA is not aware of any data that 
would render Bystolic's mechanism of action 'unique.'" 
CONCLUSION 
Beta-blockers are important class of drug in the 
management of hypertension and heart failure and in 
reducing cardiovascular risk. Nebivolol is highly 
cardioselective beta-blocker with antihypertensive efficacy 
similar to that of other beta-blockers, but with tolerability 
better than older agents in its class. It is novel in its class 
by possessing other favourable effect apart from anti 
hypertensive property. It appears to be the most selective 
β1  receptor antagonist available clinically and is devoid of 
intrinsic sympathomimetic activity, inverse agonistic 
activity, and α1 receptor blocking properties
10
. It does not 
alter exercise capacity in healthy individuals but does 
inhibit both ADP and collagen-induced platelet 
aggregation
11
. Along with peripheral vasodilatation and 
nitric oxide (NO)-induced benefits such as antioxidant 
activity and reversal of endothelial dysfunction nebivolol 
facilitates better protection from cardiovascular events
14,15
. 
Clinically, this compound has been proven to have 
antihypertensive, anti-ischemic effects, antioxidant as well 
as beneficial effects on metabolic profile.  
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